Brief: Telomir Pharmaceuticals-New Data From Preclinical Study Of Its Lead Compound, Telomir-1, In Validated Animal Model Of Werner Syndrome
05/06/2025 13:37
June 5 (Reuters) - Telomir Pharmaceuticals Inc TELO.O: TELOMIR PHARMACEUTICALS-NEW DATA FROM PRECLINICAL STUDY OF ITS LEAD COMPOUND, TELOMIR-1, IN VALIDATED ANIMAL MODEL OF WERNER SYNDROME TELOMIR PHARMACEUTICALS- ANNOUNCES TELOMIR-1 RESETS EPIGENETIC CLOCK, REVERSES DNA METHYLATION - SEC FILING Source text: [ID:n0001641172-25-013711] Further company coverage: TELO.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Telomir Pharmaceuticals
See all newsBrief: Telomir Pharmaceuticals - Alan Weichselbaum To Step Down As CFO Effective June 6, 2026 - SEC Filing
Brief: Telomir Pharmaceuticals Demonstrates Broad Tumor Cell Mortality In Human Triple-Negative Breast Cancer Models
Brief: Telomir Pharmaceuticals Telomir-1 Significantly Reduced Tumor Growth And Metastases
Brief: Telomir Pharmaceuticals Reports New Data Showing Telomir-1 Resets Cancer’S “Kill-And-Clean” Defense Systems In An Aggressive Prostate Cancer Model
U.S. STOCKS ON THE MOVE-InterDigital, Scholar Rock, Live Nation